Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Valeant Pharma Sees Bausch & Lomb Acquisition as China Entry

publication date: May 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Valeant Pharma, Canada’s largest drugmaker, announced yesterday it would pay $8.7 billion to acquire Bausch & Lomb. With the transaction, Valeant bought a substantial portfolio of eye care products, but it also acquired, for the first time, a sales foothold in China. Valeant said it would leverage B&L’s China organization to bring its own products to the PRC. More details....

Stock Symbol: (NYSE: VRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners